Ratings for Solventum (NYSE:SOLV) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
Analysts have recently evaluated Solventum and provided 12-month price targets. The average target is $64.6, accompanied by a high estimate of $70.00 and a low estimate of $54.00. This current average represents a 7.71% decrease from the previous average price target of $70.00.
The perception of Solventum by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Solventum's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Solventum analyst ratings.
Solventum is an independent healthcare company with a primary focus on solving big healthcare challenges. Its diverse product portfolio spans across the healthcare industry from medical solutions and oral care to health information systems and separation and purification sciences.
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, Solventum showcased positive performance, achieving a revenue growth rate of 0.25% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Solventum's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.76%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Solventum's ROE stands out, surpassing industry averages. With an impressive ROE of 6.53%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Solventum's ROA excels beyond industry benchmarks, reaching 1.63%. This signifies efficient management of assets and strong financial health.
Debt Management: Solventum's debt-to-equity ratio surpasses industry norms, standing at 2.16. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.